Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

TFPI Protein, Human, Recombinant (His)

Catalog No. TMPY-01030

TFPI Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 30.6 kDa and the accession number is P10646-1.

TFPI Protein, Human, Recombinant (His)

TFPI Protein, Human, Recombinant (His)

Catalog No. TMPY-01030
TFPI Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 30.6 kDa and the accession number is P10646-1.
Pack SizePriceAvailabilityQuantity
50 μg$320In Stock
100 μg$5297-10 days
200 μg$8737-10 days
500 μg$1,6907-10 days
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity
Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2. The IC50 value is < 0.4 nM, as measured in 100μL reaction mixture containing 1.25 ng trypsin, 10 μM substrate, 50 mM Tris, 10 mM CaCl2, 0.15 M NaCl, 0.05% Brij-35, pH 7.5 .
Description
TFPI Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 30.6 kDa and the accession number is P10646-1.
Species
Human
Expression System
HEK293 Cells
TagC-His
Accession NumberP10646-1
Synonyms
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor),TFPI1,TFI,LACI,EPI
Construction
A DNA sequence encoding the human TFPI (NP_006278.1) (Met 1-Lys 282) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Asp 29
Protein Purity
> 85 % as determined by SDS-PAGE
TFPI Protein, Human, Recombinant (His)
Molecular Weight30.6 kDa (predicted); 42-45 kDa (reducing condition, due to glycosylation)
Endotoxin< 1.0 EU/μg of the protein as determined by the LAL method.
FormulationLyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
ShippingIn general, Lyophilized powders are shipping with blue ice.
Research Background
Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signaling activities. It is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. With its Kunitz domains, TFPI exhibits significant homology with human inter-alpha-trypson inhibitor and bovin basic pancreatic trypsin inhibitor. TFPI is the natural inhibitor of TF coagulant and signaling activities. The importance of TFPI in the regulation of blood coagulation is emphasized by how its activity is modulated in human disease. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In addition, studies have shown that TFPI exhibits antiangiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumor cell-associated TFPI are shown to significantly reduce tumor cell-induced coagulation activation and lung metastasis.

Dose Conversion

You can also refer to dose conversion for different animals. More

Calculator

  • Reconstitution Calculator
  • Recombinant Protein Dilution Calculator
  • Specific Activity Calculator

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords